Quarterly report pursuant to Section 13 or 15(d)

Investment in Viking Therapeutics (Details)

v3.5.0.2
Investment in Viking Therapeutics (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 13 Months Ended
Apr. 13, 2016
USD ($)
shares
Apr. 30, 2016
USD ($)
$ / shares
shares
Jan. 31, 2016
USD ($)
May 31, 2015
USD ($)
$ / shares
shares
May 31, 2014
USD ($)
program
Jun. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
May 31, 2015
$ / shares
Dec. 31, 2015
USD ($)
Aug. 31, 2014
$ / shares
shares
Schedule of Equity Method Investments [Line Items]                      
Payments to acquire IPO shares             $ 700 $ 9,000      
Warrants issued in public offering (shares) | shares                     3,264,643
Exercise price | $ / shares                     $ 125.08
Proceeds received from repayment of Viking note receivable             300 $ 0      
Note receivable from Viking Therapeutics           $ 3,207 3,207     $ 4,782  
Change in fair value of the Viking convertible debt receivable and warrants           $ (200) $ (200)        
Viking                      
Schedule of Equity Method Investments [Line Items]                      
Number of programs licensed | program         5            
Loss percentage recorded                 100.00%    
Debt | Viking                      
Schedule of Equity Method Investments [Line Items]                      
Convertible loan facility         $ 2,500            
Viking Therapeutics, Inc.                      
Schedule of Equity Method Investments [Line Items]                      
Shares issued in IPO (shares) | shares   7,500,000                  
IPO share price (USD per share) | $ / shares   $ 1.25                  
IPO shares purchased by the Company (shares) | shares   560,000                  
Payments to acquire IPO shares   $ 700                  
Equity interest in outstanding common stock of Viking (percent)   32.70%       32.70% 32.70%        
Note receivable, stated interest rate (percent)     2.50%             5.00%  
LSA, lock-up period extension     1 year                
Note receivable, amount due upon consummation of capital financing transaction     $ 1,500                
Note receivable, cash due upon consummation of capital financing transaction     $ 300                
Note receivable, repayment in equity (percent)     200.00%                
Warrants issued in public offering (shares) | shares   7,500,000                  
Exercise price | $ / shares   $ 1.50                  
Public offering warrants purchased by the Company (USD per share) | shares   560,000                  
Proceeds received from repayment of Viking note receivable $ 300                    
Shares received for repayment of note receivable (shares) | shares 960,000                    
Equity Method Investment, Warrants Received, Licensing Agreement | shares 960,000                    
Value of shares and warrants received for repayment of note receivable $ 1,200                    
Decrease in investment in Viking   $ (10,000)                  
Common Stock                      
Schedule of Equity Method Investments [Line Items]                      
Aggregate value of shares received under licensing agreement       $ 29,200              
IPO shares purchased by the Company (shares) | shares       1,100,000              
Payments to acquire IPO shares       $ 9,000              
Common Stock | Viking Therapeutics, Inc. | IPO                      
Schedule of Equity Method Investments [Line Items]                      
Shares issued in IPO (shares) | shares       3,700,000              
IPO aggregate offering price       $ 29,200              
IPO share price (USD per share) | $ / shares       $ 8.00         $ 8.00    
Other Income                      
Schedule of Equity Method Investments [Line Items]                      
Short term investment gain           $ 500